La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Zevia a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Zevia..

Zevia (NYSE:ZVIA) Azioni, Catena delle Opzioni

ZEVIA PBC-A

Zevia

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

February's Jobs Report Could Tip An Already Nervous Market Into Correction Territory

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BLNE

ZVIA

Mercato in fermento: quali occasioni si celano tra i titoli meno in vista del settore? Un&#39;analisi approfondita per investitori lungimiranti.

Scopri 3 azioni sottovalutate nel settore dei beni di consumo

Zevia PBC

United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares are getting crushed in Wednesday&#8217;s after-hours session after President Donald Trump suggested he doesn&#8217;t want to see the company get <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns">acquired by Nippon Steel</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=qr9AeMFXzpY">press conference</a> from the Oval Office late Wednesday, Trump said he wants U.S. Steel to remain a U.S. company. 
&#8220;We don&#8217;t want to see it go to Japan. You know, we love Japan, but U.S. Steel is a very special company,&#8221; Trump said. 
The news comes just a day after U.S. Steel shares surged after Trump ordered a <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns">national security review</a> of the company&#8217;s takeover deal with Nippon Steel, which was blocked by the Biden Administration. 
U.S. Steel and Nippon Steel filed lawsuits in January in response to what the companies said was &#8220;wrongful interference&#8221; with Nippon's proposed $14.9-billion acquisition of U.S. Steel, originally announced at the end of 2023.
The Biden administration said last year that&nbsp;<a href="https://www.benzinga.com/news/24/07/39613777/amid-opposition-from-biden-and-workers-nippon-steel-vc-returns-to-discuss-us-steel-acquisition" target="_blank" rel="noreferrer noopener">it was &#8220;vital&#8221;</a>&nbsp;that U.S. Steel remained a domestically operated American steel company. The proposed acquisition had become a major topic of discussion leading up to the&nbsp;presidential election in November.
X Price Action: <a href="http://benzinga.com/quote/X">U.S. Steel shares</a> were down 11.39% after-hours, trading at $39.98 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008">Goldman Sachs Scraps Recession Call After Trump&#8217;s Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo: Shutterstock.

Commodities

Global

After-Hours Center

Movers

US Steel Stock Tumbles As Trump Says 'We Don't Want To See It Go To Japan'

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has secured a deal to acquire Swedish consumer health firm Karo Healthcare<a target="_blank" href="https://www.benzinga.com/25/02/43907861/kkr-to-gain-full-control-of-hcg-in-400-million-deal-eyes-healthcare-expansion" rel="noreferrer noopener">.</a>
The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months, per a <a target="_blank" href="https://eqtgroup.com/news/eqt-to-sell-karo-healthcare-a-leading-pan-european-consumer-health-platform-to-kkr-2025-04-09" rel="noreferrer noopener">statement</a>.&nbsp;
"We engaged the full capabilities of our firm to deliver this transaction during a period of market disruption and we look forward to supporting Karo's growth as a value-enhancing strategic partner," said Hans Arstad, Managing Director at KKR.
The transaction, expected to be valued at approximately 2.65 billion euros ($2.924 billion) including debt, would see KKR beat out rival bidder PAI Partners to secure the company behind popular over-the-counter brands like E45 and Lamisil, Financial Times <a target="_blank" href="https://www.ft.com/content/59680d34-adb9-473a-8c95-9f89ac9e1555" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44514266/kkr-mulls-to-buy-japan-based-eye-care-company-topcon" rel="noreferrer noopener">KKR Mulls To Buy Japan-Based Eye Care Company Topcon</a>
Karo Healthcare, headquartered in Stockholm, has expanded significantly under the ownership of EQT, which took the firm private in 2022 at a valuation of 1.4 billion euros.
EQT initially took a majority stake in Karo back in 2019 when the business was still listed, Financial Times adds.
The acquisition underscores KKR's confidence in healthcare-focused investments even as overall merger activity has slowed due to uncertain interest rate policy and fluctuating debt markets.
The buyout is poised to provide a strong return for EQT, following a series of brand acquisitions Karo made in recent years.
Under EQT's stewardship, Karo spent £200 million in 2021 to acquire the E45 skincare line from Reckitt Benckiser Group Plc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), and in 2023 it purchased Lamisil from Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) for £235 million. The company currently markets over 100 products across 90 countries, with a portfolio that includes Nutravita, Alpha Foods, and Remescar. Karo employs about 400 people globally.
This deal would further KKR's extensive footprint in the European healthcare sector.
The firm, which manages $668 billion in assets, has recently invested in U.K.-based Clinisupplies and Swiss peptide manufacturer Biosynth, among others.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, KKR stock has lost over 5% in the past year. Investors can gain exposure to the stock via FM Focus Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>).
Price Action: KKR shares closed higher by 16.90% to $110.46&nbsp;on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44706944/elon-musk-warns-those-who-financed-tesla-attacks-will-go-to-prison" target="_blank" rel="noreferrer noopener">Elon Musk Warns Those Who Financed Tesla Attacks ‘Will Go To Prison'</a></li>
</ul>
Photo via Shutterstock

Equities

Media

General

Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF

FMCX

RBGLY

KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover

Bank shares such as Ameris Bancorp inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) and BancFirst Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) are trading higher on Wednesday in response to a surprise announcement from President Donald Trump to temporarily pause certain tariffs.
What To Know: The broad-based rally followed Trump's declaration of a 90-day suspension on reciprocal tariffs for countries that have not retaliated against U.S. trade measures. While the pause excludes China — which will now face a 125% tariff on its goods — the shift in policy has eased immediate trade tensions and helped stabilize market sentiment.
A pause in trade escalation reduces uncertainty, which can support business lending, consumer confidence and overall economic activity — all key drivers for banks.
Trump's move was said to be a reward for countries that refrained from retaliating, offering them a temporary 10% tariff and delaying further duties. In contrast, China was singled out as a bad actor, with the president criticizing its trade practices and warning that the U.S. will no longer tolerate the current imbalance.
Treasury Secretary Scott Bessent described the tariff shift as a correction to decades of trade inequities and suggested that the market had previously misunderstood the scope of Trump&#8217;s policy. He called the 10% reciprocal tariff a "temporary floor" that adds clarity and leverage to U.S. trade strategy.
Price Action: Ameris shares closed Wednesday up 8.31% to $54.90 and Bancfirst shares were up 6.08% to $108.29, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Photo: Shutterstock.

ABCB

BANF

Bank Shares Are Up Today: What You Need To Know

U.S.&nbsp;President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
"We're&nbsp;going to be announcing very&nbsp;shortly a major tariff on&nbsp;pharmaceuticals… when they hear that&nbsp;they will leave China, they&nbsp;will leave other places because… most of their product&nbsp;is sold here," Trump expressed at&nbsp;a National Republican <a target="_blank" href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" rel="noreferrer noopener">Congressional Committee&nbsp;dinner</a>.
He also told reporters on board his Air Force One plane that "pharma" tariffs would arrive "at a level that you haven't really seen before," saying these would be announced "in the near future," BBC <a target="_blank" href="https://www.bbc.com/news/articles/cedyylj1v32o" rel="noreferrer noopener">report</a> added.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Trump Tariff Strategy Creates ‘Self-Inflicted Market Debacle': Analyst</a>
When President Trump announced tariffs last week, he excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">on pharmaceutical imports</a>.&nbsp;
On Wednesday, in a surprise announcement from President Donald Trump, a 90-day pause on tariffs for countries that have not retaliated <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">against U.S. trade measures.</a>
The news ignited a broad risk-on rally, catapulting major indices to multi-month highs and sending volatility plunging.
Trump's latest Truth Social post slammed China for showing "a lack of respect" and declared an immediate 125% tariff hike on Chinese goods.
"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A. and other Countries is no longer sustainable or acceptable," he said.
He praised the over 75 countries that, in his words, "have not, at my strong suggestion, retaliated in any way, shape, or form."
As a reward, those countries would benefit from a temporary 10% reciprocal tariff and a 90-day pause on additional duties.
The biopharma industry has historically been shielded from tariffs, including during Trump's first term.
Although Trump didn't provide many details, his remarks have unsettled buyers, especially those who depend on medicines from India. India provides nearly half of all generic drugs used in the U.S., helping cut billions from healthcare costs.
The U.S. is a major market, buying about a third of India's $13 billion in yearly drug exports.
Indian drug companies warn that if tariffs are added, they'd have to raise prices—which could increase healthcare costs in the U.S.
Even though some companies like Cipla and Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) have factories in the U.S., most say it's too expensive to move production for low-profit generic drugs.
BofA Securities analyst says if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a "Section 232 investigation" under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The typical timeline for a Section 232 investigation is about a year. If the same timeline applied here, tariffs on drug imports likely wouldn't take effect until late in the year—at the earliest.
It's unclear whether the Section 232 investigation into the drug industry is about to start, but based on recent comments from the administration, it seems possible. However, launching an investigation doesn't guarantee that tariffs will follow.
As the first quarter 2025 earnings season starts soon, analyst Tim Anderson says it will be worth watching whether companies discuss potential tariffs during earnings calls.
That said, any actual earnings impact likely wouldn't show up until sometime after 2025, which could leave investors with more questions than answers.
Wedbush analyst Daniel Ives <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">on Tuesday wrote</a> that "saying we can just make this in the USA" understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years."
Shares of major drugmakers such as Gilead Sciences&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly&nbsp;And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Roche&nbsp;Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi&nbsp;SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Novartis&nbsp;AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Argenx&nbsp;SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB&nbsp;SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell on Wednesday, only reverse course later after the 90-day tariff pause.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008" target="_blank" rel="noreferrer noopener">Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Analyst Color

Biotech

Government

Large Cap

Health Care

Analyst Ratings

ARGX

GILD

REGN

RHHBY

UCBJF

UCBJY

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Machinery shares such as Arcosa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACA#NYSE">ACA</a>) and Valmont Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) are trading higher Wednesday on news that President Donald Trump would pause tariffs for<a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty"> most U.S. trading partners. </a>
What To Know: The gains followed a surprise announcement from Trump of a 90-day suspension on reciprocal tariffs for all countries that have not retaliated against previous U.S. trade measures. The move excludes China, which instead will face a sharp increase in tariffs.
Trump&#8217;s decision to reward non-retaliatory nations with a temporary 10% tariff and delay further duties appears to have eased investor fears around escalating trade tensions.
In contrast, Trump sharply criticized China in a Truth Social post, accusing it of exploiting the U.S. and pledging a new 125% tariff on Chinese imports. He stated that over 75 countries had refrained from retaliating and would benefit from the pause.
At a White House press conference, Treasury Secretary Scott Bessent emphasized that the changes reflect an attempt to address long-standing global trade imbalances. He noted that markets previously misunderstood the scale of Trump&#8217;s trade measures and described the 10% reciprocal tariff as a temporary floor that adds clarity going forward.
Bessent also accused Beijing of exacerbating the trade deficit and portraying itself as an uncooperative actor in global trade. He suggested that the new policy would give the U.S. greater leverage to force changes in its trade relationship with China.
Price Action: Arcosa shares closed Wednesday up 10.67% to $78.20 and Valmont Industries shares are up 7.65% to $284.96, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2'">Benzinga Pro.</a> Read Next: • <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">Wall Street Roars As Trump Pauses Tariffs For Non-Retaliator, Hikes China Duties To 125%</a>
Photo: Shutterstock.

Machinery Stocks Are Up Today: What's Going On?

Energy Transfer's Subsidiary Energy Transfer LNG Export Enters Into A Heads Of Agreement With MidOcean Energy To Jointly Develop Lake Charles LNG Export Facility.

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares soared in afternoon trading Wednesday alongside the broader market after President Donald Trump announced a 90-day pause on reciprocal tariffs. Trump Media shares have carried that momentum into the <a href="https://www.benzinga.com/quote/DJT">after-hours session</a>.
What To Know: Stocks staged a massive rally on Wednesday after Trump announced a 90-day tariff pause in a <a href="https://truthsocial.com/@realDonaldTrump/posts/114309144289505174">post</a> on Truth Social.&nbsp;
&#8220;Based on the fact that more than 75 Countries have called Representatives of the United States &#8230; to negotiate a solution to the subjects being discussed relative to Trade, Trade Barriers, Tariffs, Currency Manipulation, and Non Monetary Tariffs, and that these Countries have not, at my strong suggestion, retaliated in any way, shape, or form against the United States, I have authorized a 90 day PAUSE,&#8221; Trump said in the post. 
The tariff pause will be effective immediately for non-retaliating countries, while China will face a harsh 125% tariff. The announcement came hours after Trump&#8217;s sweeping reciprocal tariffs took effect.
Trump Media, which is the parent company of Truth Social, was&nbsp;<a href="https://www.benzinga.com/25/04/44608924/trump-media-technology-stock-drops-on-share-registration-will-president-trump-sell-his-stake" target="_blank" rel="noreferrer noopener">co-founded by Trump</a>, who maintains more than a 50% stake in the company. 
The price action in Trump Media shares has been detached from the company's fundamentals for some time. During Trump&#8217;s 2024 presidential campaign, the stock moved up and down alongside&nbsp;Trump&#8217;s chances of reelection. Now the stock appears to be moving alongside Trump&#8217;s approval ratings. 
Trump&#8217;s approval ratings have fallen in recent months related to tariff uncertainty. Trump had approximately 47% approval when he took office in January, but Reuters reported his approval ratings had fallen to 43% as of last week.
It&#8217;s worth noting that Trump said in a Truth Social post Wednesday morning shortly after the market opened that &#8220;this is a great time to buy.&#8221; He included the ticker symbol for Trump Media in the <a href="https://truthsocial.com/@realDonaldTrump/posts/114308272725981913">post</a>. 
DJT Price Action: <a href="http://benzinga.com/quote/djt">Trump Media shares</a> closed Wednesday up 21.67% at $20.27. The stock was up another 5.82% after hours, trading at $21.45 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008">Goldman Sachs Scraps Recession Call After Trump&#8217;s Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo: Shutterstock.

Trump Media Stock Soars Hours After President Says It's A 'Great Time To Buy': What You Need To Know

Oil and gas stocks such as APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>), BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) and Exxon Mobil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are trading higher Wednesday after President Donald Trump announced a 90-day pause on reciprocal tariffs for countries that have not retaliated against <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">U.S. trade measures. </a>
What To Know: The move triggered a broad rally across energy names, driven by expectations that easing trade tensions would boost global demand and reduce export-related risks for U.S. producers. Several oil companies that have significant exposure to global oil markets have been under pressure due to fears of disrupted supply chains and reduced overseas demand. Trump&#8217;s decision to isolate China while granting tariff relief to U.S. allies shifted sentiment sharply.
The tariff pause was seen as a positive for crude demand outlook, as reduced trade friction could support broader economic activity. Energy stocks, which had lagged the broader market in recent weeks, responded to the shift in policy with a surge in buying volume, reversing recent weakness.
The focus now turns to how China will respond to the sharp 125% hike on its exports and whether energy markets will see any retaliatory impact. For now, the policy pivot has restored confidence across the oil and gas space.
Price Action: APA Corporation shares closed Wednesday up 19.10% to $16.71, Exxon Mobil shares rose 4.99% to $105.80 and BP advanced 6.81% to $27.90, according to Benzinga Pro.
Photo: Shutterstock.

Oil, Gas Stocks Jump After Trump Pauses Tariffs For US Allies, Isolates China

Earnings

CSCI

COSCIENS Biopharma Q4 EPS $(2.15) Down From $(0.85) YoY, Sales $3.30M Up From $1.20M YoY

DCTH

Delcath Systems Reveals Publication Of Comparative Analysis From Randomized Segment Of FOCUS Study In Metastatic Uveal Melanoma

FRST

Primis Financial Corp. Receives Nasdaq Notice About Delayed 10-K Filing

<h3>Gainers</h3>
<ul>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares moved upwards by 39.5% to $1.02 during Wednesday's after-market session. The company's market cap stands at $26.4 million. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares rose 18.49% to $0.38. The company's market cap stands at $6.4 million. </li>
<li>Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) shares moved upwards by 11.41% to $0.25. The company's market cap stands at $4.2 million. </li>
<li>Trump Media &amp; Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares rose 6.76% to $21.64. The market value of their outstanding shares is at $4.7 billion. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock rose 6.13% to $2.25. The company's market cap stands at $3.4 million. </li>
<li>Star Fashion Culture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) stock moved upwards by 4.99% to $0.96. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock fell 25.2% to $3.33 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock decreased by 19.22% to $0.41. The company's market cap stands at $10.8 million. </li>
<li>Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) shares declined by 8.81% to $11.5. The company's market cap stands at $1.6 billion. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) stock decreased by 8.32% to $0.52. The market value of their outstanding shares is at $9.0 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares decreased by 5.45% to $0.47. The company's market cap stands at $6.7 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock decreased by 5.01% to $0.15. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

ANTE

BAOS

CMLS

DRCT

NXPL

STBX

STFS

TNMG

TRIP

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares increased by 82.0% to $0.62 during Wednesday's after-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock rose 16.98% to $0.31. The market value of their outstanding shares is at $1.6 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 16.06% to $3.83. The company's market cap stands at $7.3 million. </li>
<li>Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) stock rose 13.22% to $1.37. The market value of their outstanding shares is at $364.5 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock rose 11.21% to $0.33. The market value of their outstanding shares is at $9.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares moved upwards by 8.8% to $2.72. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 46.2% to $4.8 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock decreased by 19.3% to $4.1. The company's market cap stands at $2.2 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock declined by 18.19% to $1.35. The company's market cap stands at $122.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock fell 17.6% to $0.01. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) shares decreased by 17.17% to $11.68. The company's market cap stands at $1.0 billion. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) stock decreased by 11.05% to $1.77. The company's market cap stands at $43.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTV

AUTL

DWTX

LGMK

LUCD

NDRA

NXTC

PCSA

RSLS

SXTP

VERO

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 7.9% to $0.47 during Wednesday's after-market session. The market value of their outstanding shares is at $6.0 million. </li>
<li>AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) shares moved upwards by 7.01% to $57.98. The company's market cap stands at $2.0 billion. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares rose 6.18% to $0.24. The market value of their outstanding shares is at $7.0 million. </li>
<li>Toppoint Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) shares rose 5.98% to $1.24. The market value of their outstanding shares is at $21.7 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock moved upwards by 5.8% to $0.39. The company's market cap stands at $7.0 million. </li>
<li>Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) stock moved upwards by 5.11% to $5.75. The market value of their outstanding shares is at $120.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares fell 11.7% to $1.13 during Wednesday's after-market session. The company's market cap stands at $2.3 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) stock declined by 9.65% to $0.02. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock decreased by 8.29% to $3.2. The company's market cap stands at $2.1 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) stock declined by 7.49% to $2.1. The company's market cap stands at $4.5 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares declined by 7.07% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) shares declined by 6.98% to $1.6. The market value of their outstanding shares is at $20.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICON

ILAG

IPDN

ONEG

RYDE

SHIP

SUNE

TOPP

UGRO

VSTE

ZCAR

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>BeLive Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIV#NASDAQ">BLIV</a>) stock moved upwards by 27.5% to $7.74 during Wednesday's after-market session. The company's market cap stands at $76.6 million. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares rose 16.78% to $0.73. The market value of their outstanding shares is at $16.1 million. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) stock increased by 9.56% to $5.5. The market value of their outstanding shares is at $9.7 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock moved upwards by 6.7% to $0.64. The company's market cap stands at $7.3 million. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 6.69% to $2.55. The market value of their outstanding shares is at $6.7 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares increased by 5.76% to $0.22. The company's market cap stands at $5.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) shares declined by 13.2% to $3.7 during Wednesday's after-market session. The company's market cap stands at $52.8 million. </li>
<li>Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares declined by 11.01% to $6.43. The company's market cap stands at $21.4 billion. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares fell 10.44% to $1.03. The company's market cap stands at $28.2 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 9.81% to $2.3. The market value of their outstanding shares is at $1.2 million. </li>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) shares decreased by 9.43% to $3.16. The market value of their outstanding shares is at $287.4 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock fell 8.09% to $0.34. The market value of their outstanding shares is at $47.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASYS

BLIV

ERIC

GREE

HTCR

INUV

IVDA

NTRP

RMNI

SVRE

12 Information Technology Stocks Moving In Wednesday's After-Market Session

LMND

Lemonade Says Identifies Technical Issue In Car Insurance Quote Flow; Says Technical Issue In Car Insurance Quote Flow Led To Exposure Of Some Data Received By Api Call To Third Party Data Provider; Says To Notify About 190,000 Individuals Affected By Data Exposure; Says Determines Data Incident Is Not Material- SEC filing

Semiconductor stocks such as Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), NVIDIA inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are trading higher Wednesday after President Donald Trump announced a 90-day pause on new tariffs for countries that have not retaliated against <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">U.S. trade measures. </a>
What To Know: The broader tech sector rallied in sync, with AMD, Microsoft, Apple, Meta and Amazon all moving higher as the market digested the policy shift. Trump's new approach — which singles out China with a steep 125% tariff while easing up on U.S. allies—was seen as a targeted realignment rather than an across-the-board escalation, giving investors more clarity around future trade impacts.
Treasury Secretary Scott Bessent emphasized that the new 10% reciprocal tariffs for allied countries would act as a temporary floor, adding a degree of near-term certainty for markets. He framed the policy as a correction to long-standing imbalances, calling China's trade position "an own goal." The move marks a sharp turn from recent blanket tariff threats and was interpreted by Wall Street as a bullish development for U.S.-based chipmakers with broad global exposure.
Price Actions: NVIDIA shares closed Wednesday up 18.72% at $114.33, Broadcom shares jumped 18.66% to $185.15 and Arm Holdings shares were up 24.20% to $106.59, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next: •<a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty"> Wall Street Roars As Trump Pauses Tariffs For Non-Retaliator, Hikes China Duties To 125%</a>
Photo: Shutterstock.

Tech

AVGO

NVDA

Chip Stocks Surge As Trump Pauses Tariffs For US Allies, Targets China With 125% Duties

Across the recent three months, 7 analysts have shared their insights on East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated East West Bancorp and provided 12-month price targets. The average target is $106.86, accompanied by a high estimate of $120.00 and a low estimate of $90.00. Highlighting a 9.88% decrease, the current average has fallen from the previous average price target of $118.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232474_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive East West Bancorp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $105.00&#x7C;$120.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $90.00&#x7C;$118.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $118.00&#x7C;$127.00 &#x7C; 
&#x7C;Matthew Clark &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $97.00&#x7C;$100.00 &#x7C; 
&#x7C;Gary Tenner &#x7C;DA Davidson &#x7C;Lowers &#x7C;Buy &#x7C; $118.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$125.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to East West Bancorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of East West Bancorp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for East West Bancorp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of East West Bancorp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EWBC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on East West Bancorp analyst ratings.</a>
<h2>About East West Bancorp</h2>
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
<h3>Understanding the Numbers: East West Bancorp's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: East West Bancorp's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.13%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: East West Bancorp's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 44.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): East West Bancorp's ROE excels beyond industry benchmarks, reaching 3.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): East West Bancorp's ROA excels beyond industry benchmarks, reaching 0.39%. This signifies efficient management of assets and strong financial health.
Debt Management: East West Bancorp's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.47, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

Deep Dive Into East West Bancorp Stock: Analyst Perspectives (7 Ratings)

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.6, a high estimate of $50.00, and a low estimate of $36.00. This current average has decreased by 0.33% from the previous average price target of $45.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232461_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Collegium Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $46.00&#x7C;$46.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$37.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Announces &#x7C;Buy &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Collegium Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Collegium Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Collegium Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Collegium Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COLL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Collegium Pharmaceutical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Collegium Pharmaceutical Better</h2>
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
<h3>A Deep Dive into Collegium Pharmaceutical's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Collegium Pharmaceutical's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 21.51%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Collegium Pharmaceutical's net margin excels beyond industry benchmarks, reaching 6.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Collegium Pharmaceutical's ROE stands out, surpassing industry averages. With an impressive ROE of 5.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.76%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.75, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COLL

What Analysts Are Saying About Collegium Pharmaceutical Stock

Ratings for UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $129.0, a high estimate of $146.00, and a low estimate of $105.00. A 5.03% drop is evident in the current average compared to the previous average price target of $135.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744232450_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of UMB Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $105.00&#x7C;$120.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$139.00 &#x7C; 
&#x7C;Brian Wilczynski &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $146.00&#x7C;$156.00 &#x7C; 
&#x7C;Benjamin Gerlinger &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $127.00&#x7C;$130.00 &#x7C; 
&#x7C;Jon Arfstrom &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $128.00&#x7C;$128.00 &#x7C; 
&#x7C;Nathan Race &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $143.00&#x7C;$142.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to UMB Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UMB Financial's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UMB Financial analyst ratings.</a>
<h2>Discovering UMB Financial: A Closer Look</h2>
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
<h3>Understanding the Numbers: UMB Financial's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: UMB Financial's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 30.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): UMB Financial's ROE excels beyond industry benchmarks, reaching 3.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): UMB Financial's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

Forecasting The Future: 6 Analyst Projections For UMB Financial

Press Releases

Zevia to Announce Third Quarter 2024 Results on Wednesday, November 6, 2024

Zevia Announces Third Quarter 2024 Results

Zevia Expands Distribution of its Better-For-You Soda into More than 4,300 Walmart Stores' "Modern Soda" Set Nationwide

Zevia to Participate in the Stephens Annual Investment Conference

Zevia Releases Holiday Ad Shining Light on Artificiality - both in Commercials and in Soda

Zevia to Participate in the 27th Annual ICR Conference

Zevia Expects Fourth Quarter 2024 Net Sales of Approximately $39.5 Million

Zevia to Announce Fourth Quarter and Full Year 2024 Results on Wednesday, February 26, 2025

Zevia Announces Fourth Quarter and Full Year 2024 Results

Zevia 'Gets the Fake Outta Here' in New Campaign Starring Country Music Superstar Jelly Roll

Embotelladora Andina S.A. Common Stock

Celsius Holdings

The Vita Coco Company, Inc. - Common Stock

Vita Coco

Coca-Cola Consolidated, Inc. - Common Stock

Coca-Cola Consolidated

National Beverage

Fomento Economico Mexicano S.A.B. de C.V. Common Stock

Fomento Economico

Keurig Dr Pepper

Coca-Cola

Coca Cola Femsa S.A.B. de C.V. American Depositary Shares, each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L Shares)

Comments

Zevia

Zevia (ZVIA) Opzioni

Zevia (NYSE:ZVIA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO